Fig. 5: Melanoma response to combination 5AZADC and ADU-S100 therapy depends on CD8+ T cells.
From: Epigenetic state determines the in vivo efficacy of STING agonist therapy
Quantitative RT-PCR analysis of Cxcl10 mRNA expression in B16-F10 tumors in STINGgt/gt mice treated with PBS, 5AZADC, ADU-S100, or 5AZADC + ADU-S100 (n = 3 biological replicates). Data are shown as mean ± SD and are representative of two independent experiments (a). Representative flow cytometry plots showing frequency of CXCR3+ CD8+ T cells in B16-F10 tumors treated with PBS, 5AZADC, ADU-S100, or 5AZADC + ADU-S100. Data are representative of two independent experiments (b). STINGgt/gt mice with B16-F10 tumors were treated with PBS or 5AZADC + ADU-S100 in combination with CD8- or CD4-depleting antibodies (see Methods). Tumor growth is shown (c). Data are shown as mean ± SEM (n = 4 mice for PBS Control, 5AZADC + ADU-S100 + α-CD4 and 5AZADC + ADU-S100 + α-CD8 and n = 5 mice for 5AZADC + ADU-S100 groups). Data are representative of two independent experiments (a–c). Statistical significance was determined by one-way (a) or two-way ANOVA (c). (ns, not significant).
